Get the Stockscreener App
18.50
2.43%
-0.46
After Hours:
18.55
0.05
+0.27%
Monte Rosa Therapeutics Inc Stock (GLUE) Forecast
The Monte Rosa Therapeutics Inc (GLUE) stock price forecast for the next 30 days is generally negative, with an average analyst price target of $2.9649, representing a -83.97% decrease from the current price of $18.50. The highest analyst price target is $2.6449, and the lowest is $3.2849.
Disclaimer: The information on this page is not intended to be financial advice. It is for general information only and should not be used to make any investment decisions. Please consult with a professional financial advisor before making any investment decisions.
12-Month GLUE Price Target
Average 2.4765
(-86.61% Downside)
Is Monte Rosa Therapeutics Inc (GLUE) A Buy Now?
Oscillators
| Name | Value | Action |
|---|---|---|
| RSI(14) | 39.98 | Neutral |
| STOCH(9,6) | 13.18 | Buy |
| STOCHRSI(14) | 3.5385 | Buy |
| MACD(12,26) | -0.2792 | Sell |
| ADX(14) | 21.80 | Neutral |
| William %R | -90.21 | Buy |
| CCI(14) | -69.12 | Neutral |
Buy: 3
Sell: 1
Neutral: 3
Summary: Neutral
Moving Averages
| Period | Simple | Exponential |
|---|---|---|
| MA10 |
19.69
Sell
|
19.75
Sell
|
| MA20 |
21.36
Sell
|
20.28
Sell
|
| MA50 |
19.36
Sell
|
19.00
Sell
|
| MA100 |
15.28
Buy
|
16.02
Buy
|
| MA200 |
10.05
Buy
|
12.57
Buy
|
Buy: 4
Sell: 6
Neutral: 0
Summary: Sell
According to our latest analysis, GLUE could be considered a Neutral, with 17 technical analysis indicators signaling 7 Buy signals, 7 signaling Sell signals and 3 Neutral signals. This suggests that investors should exercise caution when entering new positions on GLUE, as the market is likely to remain volatile in the near term.
- RSI (Relative Strength Index): The RSI(14) value of 39.98 indicates that GLUE is neither overbought nor oversold. It suggests a neutral sentiment in the short term.
- STOCH (Stochastic Oscillator): The STOCH value of 13.18 indicates that GLUE is oversold. This indicates that GLUE price is at or near the lowest level over a specified lookback period.
- STOCHRSI (Stochastic Relative Strength Index): The STOCHRSI value of 3.5385 indicates that GLUE is oversold. This suggests that GLUE price is at or near the lowest level relative to its recent price history.
- ADX (Average Directional Index): The ADX value of The ADX value of 21.8 suggests that there may be some movement in price, but it lacks strength or conviction.
- CCI (Commodity Channel Index): A CCI(14) value of A CCI(14) value of -69.12 indicates that GLUE is still oversold but not to an extreme extent.
Long-term GLUE price forecast for 2025, 2030, 2035, 2040, 2045 and 2050
Based on our analysis about Monte Rosa Therapeutics Inc financial reports and earnings history, Monte Rosa Therapeutics Inc (GLUE) stock could reach $3.6398 by 2030, $67.31 by 2040 and $44.11 by 2050. See the projected annual prices until 2050 of the Monte Rosa Therapeutics Inc stock below:
- Monte Rosa Therapeutics Inc (GLUE) is expected to reach an average price of $28.03 in 2035, with a high prediction of $28.67 and a low estimate of $28.24. This indicates an $51.49% rise from the last recorded price of $18.50.
- Monte Rosa Therapeutics Inc (GLUE) stock is projected to chart a bullish course in 2040, with an average price target of $66.75, representing an $260.83% surge from its current level. The forecast ranges from a conservative $67.35 to a sky-high $67.31.
- Our analysts predict Monte Rosa Therapeutics Inc (GLUE) to jump 560.87% by 2045, soaring from $120.52 to an average price of $122.26, potentially reaching $119.08. While $120.52 is the low estimate, the potential upside is significant.
- Monte Rosa Therapeutics Inc (GLUE) stock is expected to climb by 2050, reaching an average of $40.32, a $117.94% jump from its current level. However, a wide range of estimates exists, with high and low targets of $44.11 and $41.76, respectively, highlighting the market's uncertainty.
Monte Rosa Therapeutics Inc Stock (GLUE) Year by Year Forecast
Monte Rosa Therapeutics Inc Stock (GLUE) Price Forecast for 2026
The predicted value for Monte Rosa Therapeutics Inc (GLUE) in 2026 is set at an average of $2.5373. Estimates vary from a peak of $4.9632 to a trough of $0.1114, indicating an -86.28% surge from the present price of $18.50.
| Month | Average | Low | High | Change from today's price |
|---|---|---|---|---|
| March, 2026 | $2.8349 | $3.2849 | $2.6449 | -84.68% |
| April, 2026 | $2.1208 | $2.2308 | $2.7761 | -88.54% |
| May, 2026 | $2.7855 | $2.4932 | $2.2855 | -84.94% |
| June, 2026 | $2.3902 | $2.5502 | $2.3279 | -87.08% |
| July, 2026 | $5.1661 | $2.4814 | $2.9549 | -72.08% |
| August, 2026 | $4.3008 | $4.4196 | $4.9372 | -76.75% |
| September, 2026 | $2.6866 | $4.0666 | $3.9554 | -85.48% |
| October, 2026 | $1.0963 | $1.1513 | $1.6878 | -94.07% |
| November, 2026 | $0.931 | $1.0533 | $1.6875 | -94.97% |
| December, 2026 | $0.5981 | $0.1114 | $1.4681 | -96.77% |
Monte Rosa Therapeutics Inc Stock (GLUE) Price Forecast for 2027
For 2027, Stockscan's Analyst expects the average price target for Monte Rosa Therapeutics Inc (GLUE) is $11.92, with a high forecast of $23.83 and a low forecast of $0.0158. This indicates an -35.55% decrease from the last price of $18.50.
| Month | Average | Low | High | Change from today's price |
|---|---|---|---|---|
| January, 2027 | $2.3734 | $0.0158 | $2.4334 | -87.17% |
| February, 2027 | $0.9087 | $0.6018 | $3.6023 | -95.09% |
| March, 2027 | $13.35 | $0.2676 | $11.82 | -27.83% |
| April, 2027 | $21.47 | $19.05 | $17.77 | +16.06% |
| May, 2027 | $16.54 | $18.35 | $19.04 | -10.59% |
| June, 2027 | $23.31 | $21.93 | $23.38 | +26.02% |
| July, 2027 | $20.10 | $22.80 | $21.81 | +8.66% |
| August, 2027 | $20.42 | $20.94 | $19.55 | +10.39% |
| September, 2027 | $19.73 | $19.92 | $20.30 | +6.67% |
| October, 2027 | $24.42 | $20.91 | $21.12 | +32.01% |
| November, 2027 | $24.13 | $24.51 | $23.83 | +30.44% |
| December, 2027 | $20.72 | $21.14 | $23.47 | +12.02% |
Monte Rosa Therapeutics Inc Stock (GLUE) Price Forecast for 2028
In 2028, Monte Rosa Therapeutics Inc (GLUE) is projected to reach an average price of $17.18, with a high projection of $20.14 and a low estimate of $14.22. This indicates an -7.13% fall from the last price of $18.50.
| Month | Average | Low | High | Change from today's price |
|---|---|---|---|---|
| January, 2028 | $20.97 | $20.63 | $19.02 | +13.37% |
| February, 2028 | $20.64 | $20.77 | $19.80 | +11.58% |
| March, 2028 | $20.97 | $21.01 | $20.14 | +13.37% |
| April, 2028 | $19.69 | $20.35 | $19.51 | +6.45% |
| May, 2028 | $17.30 | $17.64 | $18.50 | -6.51% |
| June, 2028 | $17.11 | $17.12 | $17.08 | -7.49% |
| July, 2028 | $16.94 | $17.24 | $17.10 | -8.41% |
| August, 2028 | $15.71 | $16.97 | $16.71 | -15.10% |
| September, 2028 | $17.05 | $16.92 | $16.86 | -7.86% |
| October, 2028 | $15.59 | $15.83 | $16.53 | -15.70% |
| November, 2028 | $16.81 | $14.22 | $15.64 | -9.15% |
| December, 2028 | $14.36 | $14.89 | $15.22 | -22.40% |
Monte Rosa Therapeutics Inc Stock (GLUE) Price Forecast for 2029
The 2029 price forecast for Monte Rosa Therapeutics Inc Stock (GLUE) is $8.333 on average, with a high prediction of $12.87 and a low estimate of $3.7978. This represents an -54.96% decrease from the previous price of $18.50.
| Month | Average | Low | High | Change from today's price |
|---|---|---|---|---|
| January, 2029 | $12.77 | $12.88 | $12.87 | -30.99% |
| February, 2029 | $11.76 | $11.91 | $12.36 | -36.45% |
| March, 2029 | $11.30 | $11.42 | $11.41 | -38.94% |
| April, 2029 | $11.00 | $11.28 | $11.08 | -40.56% |
| May, 2029 | $11.14 | $10.78 | $10.95 | -39.80% |
| June, 2029 | $12.02 | $11.46 | $12.74 | -35.04% |
| July, 2029 | $11.66 | $11.68 | $11.40 | -36.99% |
| August, 2029 | $7.8979 | $8.8979 | $11.07 | -57.31% |
| September, 2029 | $7.7973 | $7.655 | $7.0403 | -57.85% |
| October, 2029 | $5.899 | $7.2793 | $6.9467 | -68.11% |
| November, 2029 | $4.7784 | $5.0661 | $5.6756 | -74.17% |
| December, 2029 | $3.2078 | $3.7978 | $3.9408 | -82.66% |
Monte Rosa Therapeutics Inc Stock (GLUE) Price Forecast for 2030
Monte Rosa Therapeutics Inc Stock (GLUE) is expected to reach an average price of $22.34 in 2030, with a high forecast of $41.47 and a low forecast of $3.2102. This signifies an +20.75% surge from the last price of $18.50.
| Month | Average | Low | High | Change from today's price |
|---|---|---|---|---|
| January, 2030 | $3.425 | $3.2102 | $3.6398 | -81.49% |
| February, 2030 | $36.67 | $35.00 | $36.37 | +98.22% |
| March, 2030 | $37.49 | $39.46 | $37.82 | +102.67% |
| April, 2030 | $39.85 | $36.83 | $36.69 | +115.40% |
| May, 2030 | $40.32 | $40.83 | $41.47 | +117.93% |
| June, 2030 | $39.14 | $38.44 | $38.11 | +111.57% |
| July, 2030 | $35.98 | $36.82 | $37.40 | +94.48% |
| August, 2030 | $38.61 | $37.51 | $36.07 | +108.71% |
| September, 2030 | $40.23 | $38.53 | $39.68 | +117.44% |
| October, 2030 | $36.60 | $40.37 | $39.84 | +97.86% |
| November, 2030 | $35.41 | $36.09 | $36.12 | +91.39% |
| December, 2030 | $34.44 | $35.75 | $34.72 | +86.17% |
1.24%
0.19%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):